DS, don't be dismayed, dry macular degeneration has no effective treatment. It affects many of the older population and is a mega blockbuster potential. Once it turns into wet MD it is the major cause of blindness in the aged.
Prana are looking to eliminate the problem before it gets to that stage.
The theory is there, the patents are there, but I have not seen any preclinical model work. I don't even know if there could be a preclinical model for that. Some time back I was following a biotech working on WMD and they were injecting the drug into the eyeball. That sure didn't sound like fun.
Here is the patent info
[“Method of treatment and prophylaxis and agents useful for
same"
Filed: April 13, 2007
Applicant: Prana Biotechnology Limited
Patents have been Granted in Australia, Singapore, Europe,
Japan, China and New Zealand. An application has been
Accepted in South Africa. Applications are under examination
in Israel, Canada, the USA, South Korea, India and Brazil.
Patents only directed to F4 type chemical structures have been allowed to lapse.
This invention was originally filed to claim the use of MPAC
compounds for the treatment of Age related Macular
Degeneration. The case has since been divided into two
separate applications that each contain composition of matter claims on two different chemical scaffolds.]
It would be nice if PBT2 was effective. Phase 1 safety trials were done on healthy patients and I guess it could be ready for a phase 2.
- Forums
- ASX - By Stock
- thought/opinion for board members
DS, don't be dismayed, dry macular degeneration has no effective...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
STX
Strike hands $48.5M contract to Clarke Energy to produce 20x 4.5MW gas engines for Sth Erregulla
TG1
TechGen Metals kicks off airborne geophys survey at Sally Downs copper play – a first for the permit
Add ATH (ASX) to my watchlist
|
|||||
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.28M |
Open | High | Low | Value | Volume |
0.4¢ | 0.4¢ | 0.4¢ | $8.4K | 2.1M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
67 | 79035427 | 0.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.4¢ | 115463117 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
67 | 79035427 | 0.003 |
32 | 48397013 | 0.002 |
19 | 111721101 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.004 | 115338191 | 6 |
0.005 | 39399648 | 32 |
0.006 | 20018927 | 21 |
0.007 | 51842667 | 33 |
0.008 | 26337017 | 27 |
Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |